Literature DB >> 10071128

MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation.

A Stacchini1, M Aragno, A Vallario, A Alfarano, P Circosta, D Gottardi, A Faldella, G Rege-Cambrin, U Thunberg, K Nilsson, F Caligaris-Cappio.   

Abstract

We report the establishment and characterization of two cell lines, MEC1 and MEC2, that grew spontaneously on two subsequent occasions from the peripheral blood (PB) of a patient with B-chronic lymphocytic leukemia (B-CLL) in prolymphocytoid transformation. The patient was EBV-seropositive, his leukemic cells were EBNA negative, but the spontaneously grown cell lines are EBNA-2 positive. In liquid culture MEC1 cells grow adherent to the vessel wall and as tiny clumps; MEC2 cells do not adhere and form large clumps. The doubling time of MEC1 is 40h and of MEC2 is 31h. Both cell lines express the same light (kappa) and heavy chains (mu, delta) as the fresh parental B-CLL cells at the same high intensity, share the expression of mature B cell markers (CD19, CD20, CD21, CD22), differ in the expression of CD23 and FMC7, are CD11a+, CD18+, CD44+, CD49d+, CD54+ and express at high levels both CD80 and CD86. CD5 is negative on MEC1 cells (as on the vast majority of parental cells) and it has been lost by MEC2 cells after several months of culture. The cells have a complex karyotype. The tumour origin of MEC1 and MEC2 has been demonstrated by Southern blot analysis of the IgH loci and by Ig gene DNA sequencing. They use the VH4 Ig family and have not undergone somatic mutations (94.8% homology with germline Ig gene 4-59). Cytofluorographic analysis and RT-PCR reveal that MEC1 and MEC2 overexpress Bcl-2 together with Bax, express large amounts of Bcl-xL and trace amounts of Bcl-xS.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10071128     DOI: 10.1016/s0145-2126(98)00154-4

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  109 in total

1.  Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers.

Authors:  Jason A Dubovsky; Daniel Wang; John J Powers; Emmanuel Berchmans; Matthew A Smith; Kenneth L Wright; Eduardo M Sotomayor; Javier A Pinilla-Ibarz
Journal:  Leuk Res       Date:  2010-09-22       Impact factor: 3.156

2.  The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state.

Authors:  Esmerina Tili; Jean-Jacques Michaille; Zhenghua Luo; Stefano Volinia; Laura Z Rassenti; Thomas J Kipps; Carlo M Croce
Journal:  Blood       Date:  2012-06-21       Impact factor: 22.113

3.  In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins.

Authors:  M Martínez-Moreno; M Leiva; N Aguilera-Montilla; S Sevilla-Movilla; S Isern de Val; N Arellano-Sánchez; N C Gutiérrez; R Maldonado; J Martínez-López; I Buño; J A García-Marco; P Sánchez-Mateos; A Hidalgo; A García-Pardo; J Teixidó
Journal:  Leukemia       Date:  2015-12-10       Impact factor: 11.528

4.  Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia.

Authors:  Christopher J Ott; Alexander J Federation; Logan S Schwartz; Siddha Kasar; Josephine L Klitgaard; Romina Lenci; Qiyuan Li; Matthew Lawlor; Stacey M Fernandes; Amanda Souza; Donald Polaski; Deepti Gadi; Matthew L Freedman; Jennifer R Brown; James E Bradner
Journal:  Cancer Cell       Date:  2018-11-29       Impact factor: 31.743

5.  All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism.

Authors:  Paula Fernández-Calotti; Marçal Pastor-Anglada
Journal:  J Biol Chem       Date:  2010-02-19       Impact factor: 5.157

6.  Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression.

Authors:  Pradeep Kumar Kopparapu; Sujata Bhoi; Larry Mansouri; Laleh S Arabanian; Karla Plevova; Sarka Pospisilova; Agata M Wasik; Giorgio Alberto Croci; Birgitta Sander; Marco Paulli; Richard Rosenquist; Meena Kanduri
Journal:  Epigenetics       Date:  2016-04-06       Impact factor: 4.528

7.  A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.

Authors:  Davide Bagnara; Matthew S Kaufman; Carlo Calissano; Sonia Marsilio; Piers E M Patten; Rita Simone; Philip Chum; Xiao-Jie Yan; Steven L Allen; Jonathan E Kolitz; Sivasubramanian Baskar; Christoph Rader; Hakan Mellstedt; Hodjattallah Rabbani; Annette Lee; Peter K Gregersen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

8.  ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia.

Authors:  Silvia Martinelli; Meena Kanduri; Rossana Maffei; Stefania Fiorcari; Jenny Bulgarelli; Roberto Marasca; Richard Rosenquist
Journal:  Epigenetics       Date:  2013-05-14       Impact factor: 4.528

9.  Zebularine significantly sensitises MEC1 cells to external irradiation and radiopharmaceutical therapy when administered sequentially in vitro.

Authors:  Jeffrey N Bryan; Senthil R Kumar; Fang Jia; Ethan R Balkin; Michael R Lewis
Journal:  Cell Biol Int       Date:  2013-12-09       Impact factor: 3.612

Review 10.  Tumor galectinology: insights into the complex network of a family of endogenous lectins.

Authors:  Harald Lahm; Sabine André; Andreas Hoeflich; Herbert Kaltner; Hans-Christian Siebert; Bernard Sordat; Claus-Wilhelm von der Lieth; Eckhard Wolf; Hans-Joachim Gabius
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.